All In Biotech

Drug Trial Radar · NCT02371369

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath

Last checked: Nov 20, 2026Latest source record: May 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

May 11, 2015

Primary completion

Mar 27, 2017

Study completion Apr 30, 2021

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Feb 25, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called pexidartinib for the treatment of certain tumors for which surgical removal could cause more harm than good. The main purpose of this study is to gather information about the investigational drug pexidartinib, which may help to treat tumors of pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS). The study consists of two parts with a follow-up period. In Part 1, eligible study participants will be assigned to receive either pexidartinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Some subjects, assigned to placebo in Part 1 transitioned to pexidartinib for Part 2. Then a protocol amendment was written to allow only pexidartinib patients to continue into Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label pexidartinib. There was also a follow-up period added to Part 2.

Conditions

  • Pigmented Villonodular Synovitis
  • Giant Cell Tumors of the Tendon Sheath
  • Tenosynovial Giant Cell Tumor

Interventions

  • PexidartinibDrug

    Each capsule contains 200 mg of pexidartinib for oral administration

  • PlaceboDrug

    Placebo capsule matching pexidartinib capsule for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Symptomatic, Locally Advanced Tenosynovial Giant Cell Tumor (TGCT) Achieving Complete or Partial Response to Pexidartinib Compared With That of Placebo Per Response Evaluation Criteria in Solid Tumors Version 1.1 at Week 25Time frame: Week 25

Locations

39 sites in 12 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Scottsdale, Arizona

  • University of Southern California

    Los Angeles, California

  • Stanford Cancer Center

    Palo Alto, California

  • UCLA Medical Center

    Santa Monica, California

  • Mayo Clinic Cancer Center

    Jacksonville, Florida

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • : Dana Farber Cancer Institute

    Boston, Massachusetts

  • Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • MD Anderson Cancer Center at Cooper

    Camden, New Jersey

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke Cancer Center

    Durham, North Carolina

  • OHSU Knight Cancer Institute

    Portland, Oregon

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Chris O'Brien Lifehouse

    Sydney, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Peter MacCallum Cancer Centre

    East Melbourne, Victoria, Australia

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Herlev Hospital

    Herlev, Denmark

  • Centre Leon Bérard

    Lyon, France

  • Institut Gustave Roussy

    Villejuif, France

  • HELIOS Klinikum Berlin-Buch

    Berlin, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Military Hospital-State Health Center

    Budapest, Hungary

  • Istituto Ortopedico Rizzoli

    Bologna, BO, Italy

  • Istituto Nazionale Tumori-Fondazione IRCCS

    Milan, MI, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • Radboud Univ. Medical Center

    Nijmegen, Netherlands

  • Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie

    Warsaw, Poland

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • University College Hospital

    London, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.